Our website does not fully support your browser.

We've detected that you are using an older version of Internet Explorer. Your commerce experience may be limited. Please update your browser to Internet Explorer 11 or above.

Promega's Cookie Policy

We use cookies and similar technologies to make our website work, run analytics, improve our website, and show you personalized content and advertising. Some of these cookies are essential for our website to work. For others, we won’t set them unless you accept them. To find out more about cookies and how to manage cookies, read our Cookie Policy.

Hitting the Gas: Quantitative Cell-based Bioassays to Advance Immunotherapy Programs Targeting Co-stimulatory Immune Checkpoint Receptors

Part # PS361

Abstract

Jun Wang, Michael Beck, Jamison Grailer, Jim Hartnett, Julia Gilden, Frank Fan, Mei Cong and Zhi-jie Jey Cheng
Promega Corporation, 2800 Woods Hollow Rd, Madison, WI 53711

We have developed a portfolio of functional cell-based reporter bioassays to measure the activity of biologics drugs designed to target immune checkpoint receptors including co-inhibitory (e.g. PD-1, CTLA-4, LAG-3, TIM-3) and co-stimulatory (e.g. 4-1BB, GITR, OX40, CD40, ICOS, CD28) receptors. These bioassays consist of stable cell lines that express luciferase under the precise control of receptor-mediated intracellular signals. Here we describe the application of MOA-based immune checkpoint co-stimulatory receptor bioassays for biologics drug discovery, development, potency and stability studies.

Printed in USA.